Biotech DealBook provides investors, analysts, scientists,and business development executives with key information and insight on biopharmaceutical company deals. We cover venture capital investment, M&A's, partnerships, licensing deals and IPO’s. The value of our dealreports is in translating the technical science and biopharmaceutical aspects ofeach deal. Our analysts conduct in depth primary and secondary research on eachtransaction and combine this information with company key financial data,resulting in expertly curated micro-reports.

Our research and data helps our clients with challenges suchas where to invest and innovate, where to expand the business, how to getlarger returns on investment and who to partner with. We minimises uncertaintyby providing thorough insights and deep analysis. By browsing through our dealson the Biotech DealBook app our clients can benchmark deals, understand howdeal making trends are evolving, and identify how previous deals have beenstructured when preparing for negotiations.

Our coverage of companies and new therapies also helpsscientists keep up-to-date with key innovations, identify opportunities fromemerging trends, and devise strategies for R&D with confidence.